SE0004782D0 - blocking agents - Google Patents

blocking agents

Info

Publication number
SE0004782D0
SE0004782D0 SE0004782A SE0004782A SE0004782D0 SE 0004782 D0 SE0004782 D0 SE 0004782D0 SE 0004782 A SE0004782 A SE 0004782A SE 0004782 A SE0004782 A SE 0004782A SE 0004782 D0 SE0004782 D0 SE 0004782D0
Authority
SE
Sweden
Prior art keywords
receptors
cell
specific
pathogen
compounds
Prior art date
Application number
SE0004782A
Other languages
Swedish (sv)
Inventor
Ann-Christin Koch-Schmidt
Original Assignee
Schmidt Ann Christin Koch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schmidt Ann Christin Koch filed Critical Schmidt Ann Christin Koch
Priority to SE0004782A priority Critical patent/SE0004782D0/en
Publication of SE0004782D0 publication Critical patent/SE0004782D0/en
Priority to PCT/SE2001/002892 priority patent/WO2002051869A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

On the surface of a cell there are different surface molecules, so called receptors. These receptors bind specific ligands, through which the cell becomes affected by its surroundings. Receptor molecules are also found on the surface of viruses and other pathogens. In contrast, such receptors are used for the attachment of the pathogen to a specific protein in the host and thereby for initiating the infection process. If membrane receptors of the cell are blocked, the cell will be prevented from being affected by a specific ligand, and if surface receptors of a pathogen are blocked, the pathogen will be prevented from being infectious. This invention relates to compounds, which will form very strong complexes with and thereby inhibit the biological function of for the compound specific surface structures (receptors) on cells, pathogenic microorganisms or viruses. The invention also relates to the design and preparation of such compounds for use as drugs or as tools for analytical or diagnostic purposes. The compounds comprise two or more identical protein domains interlinked by a peptide having such a length that each of the protein domains can interact simultaneously with its specific surface structure and thereby block the function of its structure. The protein domains might be human interleukin 2 (IL-2).
SE0004782A 2000-12-22 2000-12-22 blocking agents SE0004782D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0004782A SE0004782D0 (en) 2000-12-22 2000-12-22 blocking agents
PCT/SE2001/002892 WO2002051869A1 (en) 2000-12-22 2001-12-21 Compounds comprising two or more identical protein domains interlinked by a peptide having such a length that each of the protein domains can interact simultaneously with its specific cell-surface structure and thereby block the function of the structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004782A SE0004782D0 (en) 2000-12-22 2000-12-22 blocking agents

Publications (1)

Publication Number Publication Date
SE0004782D0 true SE0004782D0 (en) 2000-12-22

Family

ID=20282362

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0004782A SE0004782D0 (en) 2000-12-22 2000-12-22 blocking agents

Country Status (2)

Country Link
SE (1) SE0004782D0 (en)
WO (1) WO2002051869A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
EP2555788B1 (en) 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
WO2015056713A1 (en) * 2013-10-15 2015-04-23 国立大学法人東京大学 C-met protein agonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642585B1 (en) * 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
EP0816510A4 (en) * 1995-12-22 2001-04-11 Toray Industries Process for producing biologically active fused proteins
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists

Also Published As

Publication number Publication date
WO2002051869A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
UA99097C2 (en) Antibodies against amyloid beta 4 with glycosylated in the variable region
BR9909860A (en) Specific cd19xcd3 polypeptides and their uses
WO2002061129A3 (en) Oligonucleotide identifiers
DE60135498D1 (en) Production of Whole Antibodies in Prokaryotic Cells
EP1127170A4 (en) Human pan-hcv human monoclonal antibodies
ATE409181T1 (en) PROTEOMIMETIC COMPOUNDS AND METHODS
DE69714654D1 (en) Use of a metalloporphyrin conjugate for the detection of biological compounds
MEP35608A (en) Polyalkylene polymer compounds and uses thereof
DE69128543T2 (en) MONOCLONAL ANTIBODIES OF THE MOUSE
DE69712085D1 (en) CRYSTALLIZABLE COMPOSITIONS CONTAINING A COMPLEX OF PROTEIN DOMAIN NS3 FROM THE VIRUS OF HEPATITIS C AND NS4A, AND CRYSTALS PROVIDED THEREFORE
GB0211136D0 (en) Treatment and prevention of tissue damage
DE60033528D1 (en) FILTER MEMBRANES FOR PHYSIOLOGICALLY ACTIVE SUBSTANCES
ES2141086T3 (en) ANTIBODIES AGAINST THE LIGANDO-ANALOGS AND THEIR USE IN THE LIGANDO-RECEIVER DOSAGES.
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO1995011975A3 (en) Retroviral superantigens, superantigen peptides, and methods of use
ATE410514T1 (en) CALCIUM-BINDING RECOMBINANT ANTIBODIES AGAINST PROTEIN C
SE0004782D0 (en) blocking agents
EP1766011A4 (en) Polypeptide ligands containing linkers
BRPI0412699A (en) hydrophobic compounds and particulates and their applications
DK0764049T3 (en) Alkali resistant protein adsorbent
DK1406927T3 (en) Glycopeptides, Preparation and Use thereof for Diagnosis or Therapeutic Treatment of Disseminated Sclerosis
ATE516356T1 (en) SUPPORTED LYSOSTAPHIN MOLECULE WITH IMPROVED STAPHYLOLYTIC EFFECT
MXPA02005236A (en) Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof.
DE60017229D1 (en) DNA encoding the structural protein-1 of infectious salmon anemia virus and its uses
ATE346087T1 (en) SWINE HEPATITIS E VIRUS AND ITS USES